Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL.
Meric-Bernstam F, et al. Among authors: reynolds cm.
JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
JCO Precis Oncol. 2023.
PMID: 38096472
Free PMC article.